Trial Profile
A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-Cell Lymphomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Varlilumab (Primary)
- Indications B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Lymphomatoid granulomatosis; Non-Hodgkin's lymphoma; Plasmablastic lymphoma; Primary-Effusion-Lymphoma
- Focus Therapeutic Use
- Acronyms DIAL study
- 27 Oct 2023 Planned End Date changed from 31 Dec 2023 to 25 Oct 2024.
- 03 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 03 Jan 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.